TRCT
HZNP

Tower Research Capital (TRC)’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Tower Research Capital (TRC)’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-459
Closed -$53.1K – 6416
2023
Q3 		$53.1K Sell
459
-2,570
-85% -$276K ﹤0.01% 2500
2023
Q2 		$312K Sell
3,029
-6,410
-68% -$676K 0.01% 1270
2023
Q1 		$1.03M Buy
9,439
+3,126
+50% +$346K 0.03% 429
2022
Q4 		$718K Sell
6,313
-5,124
-45% -$426K 0.03% 520
2022
Q3 		$708K Sell
11,437
-3,840
-25% -$268K 0.01% 888
2022
Q2 		$1.22M Buy
15,277
+8,990
+143% +$851K 0.03% 584
2022
Q1 		$661K Sell
6,287
-3,709
-37% -$361K 0.01% 999
2021
Q4 		$1.08M Buy
9,996
+8,395
+524% +$916K 0.02% 659
2021
Q3 		$175K Sell
1,601
-12,806
-89% -$1.33M ﹤0.01% 1942
2021
Q2 		$1.35M Buy
14,407
+10,853
+305% +$999K 0.04% 468
2021
Q1 		$327K Sell
3,554
-2,778
-44% -$234K 0.01% 1605
2020
Q4 		$463K Sell
6,332
-4,644
-42% -$345K 0.01% 1041
2020
Q3 		$853K Buy
10,976
+9,993
+1,017% +$688K 0.01% 1129
2020
Q2 		$55K Sell
983
-2,891
-75% -$124K ﹤0.01% 2976
2020
Q1 		$114K Buy
3,874
+3,352
+642% +$113K 0.01% 948
2019
Q4 		$19K Sell
522
-2,146
-80% -$65.8K ﹤0.01% 1979
2019
Q3 		$73K Sell
2,668
-721
-21% -$18.6K 0.01% 1540
2019
Q2 		$82K Buy
3,389
+2,689
+384% +$68.2K 0.01% 1277
2019
Q1 		$19K Buy
+700
New +$16.6K ﹤0.01% 2313
2018
Q4 		– Sell
-10
Closed – – 4702
2018
Q3 		$0 Buy
+10
New +$190 ﹤0.01% 4545
2017
Q4 		– Sell
-16,463
Closed -$209K – 4341
2017
Q3 		$209K Buy
+16,463
New +$209K 0.02% 733
2017
Q2 		– Sell
-133
Closed -$2K – 3853
2017
Q1 		$2K Sell
133
-530
-80% -$8.58K ﹤0.01% 2724
2016
Q4 		$11K Buy
663
+113
+21% +$2.05K ﹤0.01% 2611
2016
Q3 		$10K Sell
550
-545
-50% -$10.6K ﹤0.01% 2097
2016
Q2 		$18K Buy
1,095
+1,052
+2,447% +$17K ﹤0.01% 2351
2016
Q1 		$1K Sell
43
-1,456
-97% -$25.5K ﹤0.01% 3910
2015
Q4 		$32K Buy
+1,499
New +$29.2K 0.01% 839
2014
Q4 		– Sell
-1,003
Closed -$12K – 5047
2014
Q3 		$12K Buy
1,003
+992
+9,018% +$11.5K ﹤0.01% 2728
2014
Q2 		$0 Sell
11
-814
-99% -$11.6K ﹤0.01% 4922
2014
Q1 		$12K Buy
+825
New +$9.32K ﹤0.01% 2464
2013
Q3 		– Sell
-2,000
Closed -$5K – 5007
2013
Q2 		$5K Buy
+2,000
New +$4.8K ﹤0.01% 2995

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Tower Research Capital (TRC)'s HZNP Position: Q4 2023 in Review

Tower Research Capital (TRC) sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 459 shares — an estimated $53.1K sold.

Tower Research Capital (TRC) first reported a position in HZNP in Q2 2013 and held it in 31 quarters. The position peaked at $1.35M in Q2 2021. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Tower Research Capital (TRC) reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 459 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $53.1K.
  • Tower Research Capital (TRC) first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2013 and held it in 31 quarters.
  • Tower Research Capital (TRC)'s Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.35M in Q2 2021.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2023, filed 13 Feb 2024.